Alyftrek (vanzacaftor, tezacaftor, deutivacaftor)

pCPA File Number: 23373

Negotiation Status:

Active Negotiation

Indication(s):

Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older

Sponsor/Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

CDA-AMC Project Number:

SR0896-000

pCPA Engagement Letter Issued:

2026-02-11

Negotiation Process Concluded:

Not Applicable